Growth Metrics

Merck (MRK) Gains from Investment Securities (2016 - 2025)

Merck (MRK) has disclosed Gains from Investment Securities for 17 consecutive years, with -$397.0 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 796.49% to -$397.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$511.0 million through Dec 2025, down 502.36% year-over-year, with the annual reading at -$511.0 million for FY2025, 502.36% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$397.0 million at Merck, down from -$129.0 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $386.0 million in Q2 2024, with the low at -$483.0 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is -$53.2 million, with a median of -$67.0 million recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 292.04% in 2024, while the deepest fall reached 1326.32% in 2024.
  • Over 5 years, Gains from Investment Securities stood at -$306.0 million in 2021, then surged by 177.78% to $238.0 million in 2022, then crashed by 91.18% to $21.0 million in 2023, then soared by 171.43% to $57.0 million in 2024, then crashed by 796.49% to -$397.0 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$397.0 million, -$129.0 million, and $124.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.